Valuation : Mabion S.A.

Market Cap 126M 33.71M 29.05M 27.23M 24.86M 46.83M 3.22B 46.98M 323M 1.63B 127M 124M 5.39B P/E 2024
-22.7x
P/E 2025 -1.8x
Enterprise Value 132M 35.4M 30.5M 28.6M 26.11M 49.18M 3.38B 49.34M 339M 1.71B 133M 130M 5.66B EV / Sales 2024
1,574,345x
EV / Sales 2025 7,560,388x
Free-Float
67.18%
Yield 2024 *
-
Yield 2025 -
1 day-0.64%
1 week-0.51%
Current month+4.56%
1 month+5.12%
3 months+4.56%
6 months-4.29%
Current year+11.75%
1 week 7.71
Extreme 7.71
8.47
1 month 7.35
Extreme 7.35
8.47
Current year 7.01
Extreme 7.01
10
1 year 6.7
Extreme 6.7
10
3 years 6.7
Extreme 6.7
23.6
5 years 6.7
Extreme 6.7
110
10 years 6.7
Extreme 6.7
139
Manager TitleAgeSince
Chief Executive Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 2021-02-22
Chairman 60 2021-05-12
Director/Board Member 53 -
Change 5-day change 1-year change 3-year change Capi.($)
-0.64%-0.51%-16.13%-52.44% 33.71M
-1.59%-3.35%+52.37%+91.62% 69.54B
-1.34%-0.75%+48.21%+92.23% 64.97B
+0.30%-0.69%+52.56%+9.51% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-0.51%+0.23%+35.77%-19.61% 19.98B
-1.91%-4.37%+13.28%+557.93% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -1.88%-1.78%+50.38%+166.88% 28.2B
Weighted average by Cap. -1.93%-1.50%+53.72%+150.38%

Financials

2024 2025
Net sales 69.02 18.45 15.9 14.91 13.61 25.64 1.76K 25.72 176.9 890.35 69.29 67.78 2.95K 15.76 4.21 3.63 3.4 3.11 5.85 402.67 5.87 40.39 203.27 15.82 15.47 674
Net income -6.33M -1.69M -1.46M -1.37M -1.25M -2.35M -162M -2.36M -16.23M -81.71M -6.36M -6.22M -271M -62.61M -16.74M -14.43M -13.53M -12.35M -23.26M -1.6B -23.34M -160M -808M -62.86M -61.49M -2.68B
Net Debt -35.18M -9.41M -8.11M -7.6M -6.94M -13.07M -899M -13.11M -90.18M -454M -35.32M -34.55M -1.51B 6.32M 1.69M 1.46M 1.36M 1.25M 2.35M 161M 2.35M 16.19M 81.48M 6.34M 6.2M 270M
Logo Mabion S.A.
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Employees
202
Date Price Change Volume
26-08-28 PLN 7.800 -0.64% 19,266
26-08-27 PLN 7.850 -0.38% 56,855
26-08-26 PLN 7.880 +2.07% 247,262
26-08-25 PLN 7.720 -1.53% 17,097
26-08-24 PLN 7.840 0.00% 18,872

Quarterly revenue - Rate of surprise